Breaking News, Financial News

Financial Report: Lilly

Revenue up 5% in the quarter to $5.7 billion.

By: Contract Pharma

Contract Pharma Staff

Lilly 3Q Revenues: $5.7 billion (+5%) 3Q Earnings: $1.2 billion (-4%)   YTD Revenues: $17.0 billion (+6%) YTD Earnings: $4.1 billion (+14%) Comments: Key growth products launched since 2014, consisting of Taltz, Trulicity, Verzenio, Jardiance, Olumiant, Emgality, Tyvyt, Baqsimi, Cyramza, Retevmo and Basaglar contributed nearly 9 percentage points of revenue growth and represented approximately 52% of total revenue for the quarter. Talz sales were $454.5 million, up 34%. Trulicity sales were...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters